Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

High materiality8/10

Shattuck Labs reports strong SL-325 Phase 1 data; Crohn's 2b on track and cash runway to 2029

Aug 11, 2026, 6:18 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Clinical milestones (Phase 2b initiation, data readouts) and a strengthened balance sheet reduce execution risk and extend runway, potentially supporting a re-rating of STTK as pipeline progress compounds with capital efficiency.

AI summary

What happened, with direct paths to the underlying reporting

Shattuck Labs reports Phase 1 SL-325 data showing favorable safety and durable TL1A-DR3 blockade, with a Q3 2026 start planned for RECEPTIVE-CD1 Phase 2b in Crohn's disease. The company also advances SL-846 with an IND-enabling program and a 2027 data readout, while maintaining a robust cash runway into 2029, collectively signaling potential near-term clinical catalysts and longer-term growth optionality in the DR3 axis.

Phase 1 SL-325 shows favorable safety and durable TL1A-DR3 blockade.
Antidrug antibodies detected in 3.7% of participants.
RECEPTIVE-CD1 Phase 2b Crohn's trial to start in Q3 2026.
SL-846 bispecific; initial data expected in 2027.
Cash and equivalents reach $208.3M as of 6/30/2026; runway to 2029.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.